Calmer weather helps contain Oakland, California, fire that forced evacuations
Expelled Indian high commissioner denies involvement in murder of Sikh leader in Canada
Two missing Navy aviators declared dead days after aircraft crash in Washington state
Iraq's Kurdish region goes to the polls with a flagging economy and political infighting top of mind
Yehuda Bauer, prominent Israeli Holocaust scholar, dies at 98
Perplexity AI in funding talks to more than double valuation to $8 billion, WSJ reports
Black patients less likely to receive certain pain relief post-surgery, new research suggests
Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI
No. 2 Georgia is still the top dog in the SEC after convincing win over previously top-ranked Texas
Browns QB Deshaun Watson suffers likely season-ending Achilles tendon injury in loss to Bengals
PARIS (Reuters) - France will take a stake in Sanofi's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. private equity firm Clayton Dubilier & Rice (CD&R) is to take a 51% stake in the company that makes of one of France's most-sold painkillers, Doliprane.
The plan for Public Investment Bank (BPI) to take a 1% stake in Opella, for about 150 million euros ($162.98 million), came through a tri-party agreement between Sanofi, the French state and CD&R and was approved by Sanofi's board on Sunday, the newspaper said.
Finance minister Antoine Armand had said earlier this week that the government was looking at all options regarding Opella, including the state being on Opella's board of directors.
($1 = 0.9204 euros)
(Reporting by Juliette Jabkhiro; Editing by Ros Russell)
